

American College of Rheumatology/European League Against Rheumatism
definition of remission in rheumatoid arthritis for clinical trials

Arthritis and Rheumatism

63, 573-586

DOI: [10.1002/art.30129](https://doi.org/10.1002/art.30129)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R83.	1.6	192
4	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258.	2.0	32
5	Limited Health Literacy Is a Common Finding in a Public Health Hospital's Rheumatology Clinic and Is Predictive of Disease Severity. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 236-241.	0.5	37
6	Clinical aspects of rheumatoid arthritis: highlights from the 2010 ACR conference (Part II). <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 393-399.	0.3	3
7	Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. <i>Yearbook of Medicine</i> , 2011, 2011, 7-9.	0.1	0
8	Treating rheumatoid arthritis to target: the patient version of the international recommendations. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 891-895.	0.5	80
9	The new classification criteria for rheumatoid arthritis and their impact on therapeutic decisions. <i>Joint Bone Spine</i> , 2011, 78, 539-541.	0.8	5
10	Rheumatoid arthritis: What is refractory disease and how to manage it?. <i>Autoimmunity Reviews</i> , 2011, 10, 707-713.	2.5	27
11	The use of conventional disease-modifying anti-rheumatic drugs in established RA. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 523-533.	1.4	16
12	Assessment of control of rheumatoid arthritis disease activity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 497-507.	1.4	20
13	What is the outcome of RA in 2011 and can we predict it?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 485-496.	1.4	23
14	Established rheumatoid arthritis: Rationale for best practice "Physicians"™ perspective of how to realise tight control in clinical practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 509-521.	1.4	17
15	Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1949-1956.	0.5	71
17	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 929-936.	1.5	391
18	To improve outcomes we must define and measure them: Toward defining remission in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 587-589.	6.7	22
19	A graphic demonstration that the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate is overly sensitive when erythrocyte sedimentation rates are low: Comment on the article by Smolen and Aletaha. <i>Arthritis and Rheumatism</i> , 2011, 63, 2149-2149.	6.7	1
20	Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. <i>Arthritis and Rheumatism</i> , 2011, 63, 3204-3215.	6.7	75
21	A suggestion and the larger perspective on the American College of Rheumatology/European League Against Rheumatism remission definitions: Comment on the article by Felson et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3643-3644.	6.7	3

#	ARTICLE	IF	CITATIONS
22	Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3642-3643.	6.7	14
23	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711.	6.7	122
24	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1986-1990.	0.5	25
25	2011 remission criteria are a new benchmark for RA therapy. <i>Nature Reviews Rheumatology</i> , 2011, 7, 317-318.	3.5	8
26	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	0.9	12
27	Later Comes Earlier, Nowadays. <i>Journal of Rheumatology</i> , 2011, 38, 2287-2289.	1.0	5
28	An observational study of tocilizumab and TNF- α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. <i>Rheumatology</i> , 2011, 50, 2093-2099.	0.9	21
29	Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 23-27.	0.6	18
30	New remission criteria for RA: "modern times" in rheumatology "not a silent film, rather a 3D movie. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 401-403.	0.5	15
31	Inclusion Criteria Based on DAS28 Score: Strength of Improvement Is Less Dependent on Baseline Disease Activity Than Expected. <i>Journal of Rheumatology</i> , 2011, 38, 1820-1820.	1.0	1
32	Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1815-1821.	0.5	90
33	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980.	0.5	54
34	Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 792-798.	0.5	185
35	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71
36	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1316-1321.	0.5	160
37	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 206-212.	0.5	31
38	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 799-803.	0.5	97
39	Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i89-i92.	0.5	26

#	ARTICLE	IF	CITATIONS
40	The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity. <i>Journal of Rheumatology</i> , 2012, 39, 2071-2080.	1.0	46
41	Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 33-37.	0.5	26
42	The risk of comorbidity: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 635-637.	0.5	30
43	Progression of joint damage despite control of inflammation in rheumatoid arthritis: a role for cartilage damage driven synovial fibroblast activity: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 793-795.	0.5	16
44	Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy—a pilot study. <i>Rheumatology</i> , 2012, 51, 1942-1952.	0.9	22
45	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.5	53
46	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1702-1705.	0.5	109
47	The importance of understanding the molecular mechanisms of resistance to biologics. <i>Rheumatology</i> , 2012, 51, 397-398.	0.9	1
49	Efficacy and Safety of CE-224,535, an Antagonist of P2X ₇ Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate. <i>Journal of Rheumatology</i> , 2012, 39, 720-727.	1.0	209
50	Defining remission in patients with RA in clinical practice. <i>Nature Reviews Rheumatology</i> , 2012, 8, 445-447.	3.5	4
51	Defining remission in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i86-i88.	0.5	42
52	Combination etanercept and methotrexate provides better disease control in very early (≤ 4 months) versus early rheumatoid arthritis (> 4 months and ≤ 2 years): post hoc analyses from the COMET study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 989-992.	0.5	74
53	Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 534-540.	0.5	36
54	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1472-1477.	0.5	86
55	Remission in Early Rheumatoid Arthritis: Predicting Treatment Response. <i>Journal of Rheumatology</i> , 2012, 39, 470-475.	1.0	33
56	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.5	131
57	Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. <i>Journal of Rheumatology</i> , 2012, 39, 1139-1145.	1.0	57
58	Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. <i>Modern Rheumatology</i> , 2012, 22, 209-215.	0.9	12

#	ARTICLE	IF	CITATIONS
59	Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. <i>Modern Rheumatology</i> , 2012, 22, 370-375.	0.9	16
60	The importance of patient participation in measuring rheumatoid arthritis flares. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1107-1109.	0.5	25
61	Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. <i>Rheumatology</i> , 2012, 51, 670-678.	0.9	17
62	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1942-1949.	0.5	59
63	Remission in Early Rheumatoid Arthritis – A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. <i>Journal of Rheumatology</i> , 2012, 39, 1155-1158.	1.0	32
64	Rheumatoid arthritis. <i>Nurse Practitioner</i> , 2012, 37, 16-22.	0.2	10
65	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2012, , .	1.5	0
66	Regulatory Aspects of New Medicines Targeted at Treatment of Autoimmune Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 739-742.	2.3	2
68	Review of Discontinuation of Infliximab in Rheumatoid Arthritis with Clinical Remission. <i>Orthopedics & Traumatology</i> , 2012, 61, 204-207.	0.0	0
69	Initial Management of Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 311-325.	0.8	18
70	Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?. <i>Arthritis Care and Research</i> , 2012, 64, 1846-1854.	1.5	32
71	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012, 64, 3850-3855.	6.7	68
72	Adherence to uric acid treatment guidelines in a rheumatology clinic. <i>Clinical Rheumatology</i> , 2012, 31, 1707-1711.	1.0	11
73	¿Debemos usar los factores de mal pronóstico para iniciar precozmente un tratamiento biológico en los pacientes con artritis reumatoide?. <i>Reumatología Clínica</i> , 2012, 8, 163-167.	0.2	1
74	Autofeedback from Ultrasound Images Provides Rapid Improvement in Palpation Skills for Identifying Joint Swelling in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1207-1214.	1.0	18
75	Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 824-830.	0.9	6
76	Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 681-686.	0.5	150
77	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.5	82

#	ARTICLE	IF	CITATIONS
78	Taking advances from bench to bedside during the last decade. Best Practice and Research in Clinical Rheumatology, 2012, 26, 225-236.	1.4	5
79	Patient's global assessment of disease activity: What are we measuring?. Arthritis and Rheumatism, 2012, 64, 2811-2813.	6.7	23
80	Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis and Rheumatism, 2012, 64, 2814-2823.	6.7	218
81	Brief Report: To squeeze or not to squeeze, that is the question! Optimizing the Disease Activity Score in 28 joints by adding the squeeze test of metatarsophalangeal joints in early rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3095-3101.	6.7	9
82	Evolution of treatment for rheumatoid arthritis. Rheumatology, 2012, 51, vi28-vi36.	0.9	139
83	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology, 2012, 51, 2020-2026.	0.9	78
84	Should modern imaging be part of remission criteria in rheumatoid arthritis?. Best Practice and Research in Clinical Rheumatology, 2012, 26, 767-785.	1.4	43
86	Can the Medication in Patients With Rheumatoid Arthritis in Remission Be Stopped?. Reumatologia Clínica (English Edition), 2012, 8, 39-41.	0.2	1
87	Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?. Reumatologia Clínica (English Edition), 2012, 8, 163-167.	0.2	1
88	Évaluation de l'impact des recommandations de la Haute Autorité de santé sur la prise en charge thérapeutique de la polyarthrite rhumatoïde en pratique courante. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 ogBT /Over	0.7	0
89	My Treatment Approach to Rheumatoid Arthritis. Mayo Clinic Proceedings, 2012, 87, 659-673.	1.4	85
91	Bone Density and Microarchitecture: Relationship Between Hand, Peripheral, and Axial Skeletal Sites Assessed by HR-pQCT and DXA in Rheumatoid Arthritis. Calcified Tissue International, 2012, 91, 343-355.	1.5	29
92	Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Research and Therapy, 2012, 14, R156.	1.6	27
93	Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study.. Arthritis Research and Therapy, 2012, 14, R112.	1.6	59
94	Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Research and Therapy, 2012, 14, R68.	1.6	83
95	Biologic Treatment in Rheumatoid Arthritis. , 0, , .		0
96	Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis. Open Access Rheumatology: Research and Reviews, 2012, 4, 9.	0.8	3
97	Transition of Care in Rheumatology: Managing the Rheumatic Patient from Childhood to Adulthood. , 0, , .		0

#	ARTICLE	IF	CITATIONS
98	Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 1-18.	2.2	7
99	Estratgia de troca entre agentes anti-TNF-alfa no melhora a capacidade funcional em pacientes com artrite reumatoide de longa evoluo. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 9-15.	0.8	5
100	It Means Everything: Continuing Normality of Everyday Life for People with Rheumatoid Arthritis in Early Remission. <i>Musculoskeletal Care</i> , 2012, 10, 162-170.	0.6	28
101	Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. <i>Arthritis Care and Research</i> , 2012, 64, 658-667.	1.5	33
102	Inactive disease and remission in childhoodonset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 683-693.	1.5	34
103	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. <i>Arthritis Care and Research</i> , 2012, 64, 640-647.	1.5	566
104	Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. <i>Arthritis and Rheumatism</i> , 2012, 64, 1316-1322.	6.7	45
105	2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
106	Role of interleukin6 in stress, sleep, and fatigue. <i>Annals of the New York Academy of Sciences</i> , 2012, 1261, 88-96.	1.8	208
107	Measures in rheumatoid arthritis: are we measuring too many parameters. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 239-248.	0.9	18
109	Ultrasound-Defined Remission and Active Disease in Rheumatoid Arthritis: Association with Clinical and Serologic Parameters. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 761-767.	1.6	36
111	Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring. <i>Arthritis Research and Therapy</i> , 2013, 15, 104.	1.6	3
112	Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis - a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2013, 15, R4.	1.6	67
113	Tocilizumab versus adalimumab for rheumatoid arthritis. <i>Lancet, The</i> , 2013, 382, 394-395.	6.3	3
114	Ultrasound Joint Inflammation in Rheumatoid Arthritis in Clinical Remission: How Many and Which Joints Should Be Assessed?. <i>Arthritis Care and Research</i> , 2013, 65, 512-517.	1.5	77
115	Standardized grip strength as an outcome measure in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 289-293.	0.6	23
117	Glucocorticoids in Rheumatoid Arthritis. <i>Drugs</i> , 2013, 73, 31-43.	4.9	18
118	Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. <i>Annals of Medicine</i> , 2013, 45, 357-363.	1.5	65

#	ARTICLE	IF	CITATIONS
119	Structural progression in rheumatoid arthritis remission: can MRI predict it?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 465-470.	0.3	0
120	Imaging in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 499-522.	1.4	51
123	Outcome Assessments in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2013, 15, 370.	2.1	12
124	Rheumatoid Arthritis in the Elderly in the Era of Tight Control. <i>Drugs and Aging</i> , 2013, 30, 863-869.	1.3	18
125	Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 291-296.	0.9	7
126	Treating rheumatoid arthritis to target: recommendations assessment questionnaire in Korea. <i>Clinical Rheumatology</i> , 2013, 32, 1791-1797.	1.0	3
127	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013, 23, 623-633.	0.9	31
128	Sustained Beneficial Effects of a Protocolized Treat-to-Target Strategy in Very Early Rheumatoid Arthritis: Three-Year Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1219-1226.	1.5	70
129	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , 2013, 52, 1202-1207.	0.9	79
130	The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab. <i>Clinical Rheumatology</i> , 2013, 32, 123-127.	1.0	11
131	Contribution of assessing forefoot joints in early rheumatoid arthritis patients: Insights from item response theory. <i>Arthritis Care and Research</i> , 2013, 65, 212-219.	1.5	5
132	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38.	6.7	225
133	Concordance clinique et Â©chographique dans la polyarthrite rhumatoÃ©de. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 569-576.	0.0	2
134	Persistent undifferentiated arthritis successfully treated with the Japanese herbal medicine â©Eppikajutsutoâ©E. <i>European Journal of Integrative Medicine</i> , 2013, 5, 184-188.	0.8	3
135	Concordance between clinical and ultrasound findings in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2013, 80, 597-603.	0.8	24
136	Camera Phone-Based Quantitative Analysis of C-Reactive Protein ELISA. <i>IEEE Transactions on Biomedical Circuits and Systems</i> , 2013, 7, 655-659.	2.7	50
137	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. <i>Lancet, The</i> , 2013, 381, 451-460.	6.3	610
138	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6Â©months of abatacept treatment in routine clinical practice. <i>The ALTAIR study. Modern Rheumatology</i> , 2013, , 1.	0.9	0

#	ARTICLE	IF	CITATIONS
139	Validation of the Methotrexate-First Strategy in Patients With Early, Poor Prognosis Rheumatoid Arthritis: Results From a Two-Year Randomized, Double-Blind Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1985-1994.	6.7	62
140	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.5	183
141	Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii124-ii127.	0.5	44
142	Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. <i>Clinical Rheumatology</i> , 2013, 32, 1347-1355.	1.0	29
143	Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. <i>BMJ Open</i> , 2013, 3, e003554.	0.8	42
144	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
145	In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 245-249.	0.5	80
146	Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents. <i>Journal of Rheumatology</i> , 2013, 40, 1967-1976.	1.0	43
147	Remission in Rheumatoid Arthritis: A Comparison of the 2 Newly Proposed ACR/EULAR Remission Criteria with the Rheumatoid Arthritis Disease Activity Index-5, a Patient Self-report Disease Activity Index. <i>Journal of Rheumatology</i> , 2013, 40, 394-400.	1.0	12
148	Polyarthrite rhumatoïde. , 2013, , 97-136.		0
149	Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 880-889.	6.7	64
150	Adding New Perspectives to the Kaleidoscope of Remission Criteria in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 353-355.	1.0	2
151	Documenting the Value of Care for Rheumatoid Arthritis, Analogous to Hypertension, Diabetes, and Hyperlipidemia: Is Control of Individual Patient Self-Report Measures of Global Estimate and Physical Function More Valuable Than Laboratory Tests, Radiographs, Indices, or Remission Criteria?. <i>Journal of Rheumatology</i> , 2013, 40, 1469-1474.	1.0	5
152	Different Wording of the Patient Global Visual Analogue Scale (PGVAS) Affects Rheumatoid Arthritis Patients' Scoring and the Overall Disease Activity Score (DAS28): A Cross-Sectional Study. <i>Musculoskeletal Care</i> , 2013, 11, 229-237.	0.6	31
153	Patient self-assessment and physician's assessment of rheumatoid arthritis activity: which is more realistic in remission status? A comparison with ultrasonography. <i>Rheumatology</i> , 2013, 52, 2243-2250.	0.9	24
154	Performance of Matrix-Based Risk Models for Rapid Radiographic Progression in a Cohort of Patients With Established Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 526-533.	1.5	26
155	A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. <i>Modern Rheumatology</i> , 2013, 23, 245-253.	0.9	8
156	Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 43-50.	0.5	259

#	ARTICLE	IF	CITATIONS
157	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 204-210.	0.5	160
158	Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. <i>Current Medical Research and Opinion</i> , 2013, 29, 85-92.	0.9	24
159	Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1823-1830.	1.0	26
160	Can Remission in Rheumatoid Arthritis Be Assessed Without Laboratory Tests or a Formal Joint Count? Possible Remission Criteria Based on a Self-report RAPID3 Score and Careful Joint Examination in the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 386-393.	1.0	25
161	Combination therapy in rheumatoid arthritis: always the best option?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 501-506.	0.3	0
163	Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate. <i>Modern Rheumatology</i> , 0, , 1.	0.9	1
164	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. <i>Arthritis Research and Therapy</i> , 2013, 15, R221.	1.6	28
165	Shorter disease duration is important for tocilizumab to achieve Boolean remission. <i>Modern Rheumatology</i> , 2013, 23, 1192-1197.	0.9	2
166	Tofacitinib for rheumatoid arthritis. <i>The Cochrane Library</i> , 0, , .	1.5	2
167	Evolving Definitions of Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1645-1653.	0.9	49
168	Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. <i>Journal of Medical Investigation</i> , 2013, 60, 77-90.	0.2	18
169	Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 403.	0.9	6
170	Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany. <i>Open Access Rheumatology: Research and Reviews</i> , 2013, 5, 51.	0.8	6
171	Biomarkers of Inflammatory Arthritis and Proteomics. , 2013, , .		0
172	Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	71
173	Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs. <i>Clinical Epidemiology</i> , 2014, 6, 221.	1.5	6
174	How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 368.	0.8	72
175	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. <i>Arthritis Care and Research</i> , 2014, 66, 1597-1603.	1.5	11

#	ARTICLE	IF	CITATIONS
176	Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 415-430.	0.3	2
177	Gastroesophageal reflux disease in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2014, 24, 291-295.	0.9	16
178	Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	1.4	21
179	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. <i>Modern Rheumatology</i> , 2014, 24, 42-51.	0.9	11
180	Rheumatoid Arthritis: Are Current Research-based Guidelines Clinically Relevant?. <i>Journal of Rheumatology</i> , 2014, 41, 1569-1570.	1.0	2
181	The Effect of Different Remission Definitions on Identification of Predictors of Both Point and Sustained Remission in Rheumatoid Arthritis Treated with Anti-TNF Therapy. <i>Journal of Rheumatology</i> , 2014, 41, 1607-1613.	1.0	19
182	Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate. <i>Modern Rheumatology</i> , 2014, 24, 681-684.	0.9	6
183	Effect of Remission Definition on Healthcare Cost Savings Estimates for Patients with Rheumatoid Arthritis Treated with Biologic Therapies. <i>Journal of Rheumatology</i> , 2014, 41, 1600-1606.	1.0	2
184	Detection of Subclinical Synovitis with Macrophage Targeting and Positron Emission Tomography in Patients with Rheumatoid Arthritis without Clinical Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2145-2152.	1.0	28
185	Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	8
186	Outcome Measures in Rheumatoid Arthritis. , 2014, , 127-140.		0
187	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. <i>Modern Rheumatology</i> , 2014, 24, 390-398.	0.9	100
188	Health Literacy Predicts Discrepancies Between Traditional Written Patient Assessments and Verbally Administered Assessments in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 256-264.	1.0	8
189	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 561-566.	0.9	9
190	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 327-339.	0.3	0
191	Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial. <i>Journal of Rheumatology</i> , 2014, 41, 2379-2385.	1.0	6
192	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. <i>Rheumatology</i> , 2014, 53, 1075-1086.	0.9	37
193	Earlier Time to Remission Predicts Sustained Clinical Remission in Early Rheumatoid Arthritis – Results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014, 41, 2161-2166.	1.0	44

#	ARTICLE	IF	CITATIONS
194	A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort. <i>Arthritis and Rheumatology</i> , 2014, 66, 1472-1481.	2.9	46
195	Stopping Anti-TNF Agents in Patients with Crohn's Disease in Remission. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 757-766.	0.9	30
196	The Value of Magnetic Resonance Imaging in Clinical Practice. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 211-214.	0.5	0
197	Association of Bone Edema with the Progression of Bone Erosions Quantified by Hand Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis in Remission. <i>Journal of Rheumatology</i> , 2014, 41, 1623-1629.	1.0	19
198	Is a Patient Questionnaire Without a Joint Examination as Undesirable as a Joint Examination Without a Patient Questionnaire?. <i>Journal of Rheumatology</i> , 2014, 41, 619-621.	1.0	6
199	Measuring Flares in Rheumatoid Arthritis. (Why) Do We Need Validated Criteria?. <i>Journal of Rheumatology</i> , 2014, 41, 189-191.	1.0	9
201	Inhibition of JNK in synovium by treatment with golimumab in rheumatoid arthritis. <i>Rheumatology International</i> , 2014, 34, 125-130.	1.5	5
202	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. <i>Joint Bone Spine</i> , 2014, 81, 409-415.	0.8	21
203	Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 417.	2.1	13
204	Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity. <i>Arthritis Care and Research</i> , 2014, 66, 190-196.	1.5	56
205	Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed Rheumatoid Arthritis: Associations with Progressive Joint Destruction and Functional Impairment. <i>Journal of Rheumatology</i> , 2014, 41, 1061-1066.	1.0	34
206	Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. <i>Rheumatology</i> , 2014, 53, 562-569.	0.9	51
207	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 447-457.	1.6	80
208	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritis. <i>Advances in Therapy</i> , 2014, 31, 780-802.	1.3	2
209	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2094-2100.	0.5	45
210	Patients with Rheumatoid Arthritis in Clinical Remission Manifest Persistent Joint Inflammation on Histology and Imaging Studies. <i>Journal of Rheumatology</i> , 2014, 41, 2153-2160.	1.0	32
211	Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs?. <i>Journal of Rheumatology</i> , 2014, 41, 1576-1582.	1.0	31
212	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. <i>Journal of Rheumatology</i> , 2014, 41, 398-406.	1.0	71

#	ARTICLE	IF	CITATIONS
213	A non-inferiority trial of an attenuated combination strategy (â€ˆCOBRA-lightâ€™) compared to the original COBRA strategy: clinical results after 26â€ˆ...weeks. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1071-1078.	0.5	91
214	Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study. <i>Joint Bone Spine</i> , 2014, 81, 426-432.	0.8	43
215	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 75-85.	0.5	139
216	The need to define treatment goals for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014, 10, 567-571.	3.5	43
217	Prevalence and incidence of rheumatoid arthritis in Italy. <i>Rheumatology International</i> , 2014, 34, 659-664.	1.5	76
218	Remission criteria and activity indices in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 1323-1330.	1.0	42
219	Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. <i>Clinical Rheumatology</i> , 2014, 33, 1061-1066.	1.0	28
220	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	1.6	108
221	Advantages of a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and feet: does the RAMRIS of the hand alone underestimate disease activity and progression?. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 104.	0.8	15
222	Clinical and Serological Predictors of Remission in Rheumatoid Arthritis Are Dependent on Treatment Regimen. <i>Journal of Rheumatology</i> , 2014, 41, 1298-1303.	1.0	12
223	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Oencia [®] as Biological Intensive Treatment for RA (ORBIT) study. <i>Modern Rheumatology</i> , 2014, 24, 754-762.	0.9	15
224	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	6.3	232
225	Revising DAS28 scores for remission in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 269-272.	1.0	20
226	The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 154-159.	0.8	14
227	Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. <i>Arthritis Research and Therapy</i> , 2014, 16, R158.	1.6	40
228	THU0181â€ˆ...Short-Lasting Flares and HAQ Impairment in Rheumatoid Arthritis Patients in Remission According to the New Acr/Eular Criteria. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 244.1-244.	0.5	0
229	The future of treatment for juvenile idiopathic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 135-146.	0.3	0
230	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. , 2014, , CD007649.		14

#	ARTICLE	IF	CITATIONS
231	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2014, , CD010455.	1.5	61
232	Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 151-160.	1.5	15
233	I. Rheumatoid Arthritis. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 2110-2117.	0.0	0
234	Fatal Complication of <i>Legionella pneumophila</i> Pneumonia in a Tocilizumab-treated Rheumatoid Arthritis Patient. Internal Medicine, 2015, 54, 1125-1130.	0.3	10
235	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open, 2015, 1, e000019-e000019.	1.8	90
236	Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis. SpringerPlus, 2015, 4, 607.	1.2	1
237	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Research and Therapy, 2015, 17, 157.	1.6	37
238	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. International Journal of Clinical Rheumatology, 2015, 10, 425-431.	0.3	0
239	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 203.	1.6	23
240	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 245.	1.6	22
241	Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Research and Therapy, 2015, 17, 266.	1.6	39
242	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Research and Therapy, 2015, 17, 343.	1.6	13
243	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-blind, Placebo/Active-controlled, Dose-ranging Study. Arthritis and Rheumatology, 2015, 67, 2591-2600.	2.9	86
244	Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2015, 8, CMAMD.S22155.	0.3	5
245	Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1619-1626.	1.5	65
246	Comprehensive Appraisal of Magnetic Resonance Imaging Findings in Sustained Rheumatoid Arthritis Remission: A Substudy. Arthritis Care and Research, 2015, 67, 929-939.	1.5	30
247	Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis. Genetics and Molecular Research, 2015, 14, 15652-15659.	0.3	11
248	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. Current Biomarker Findings, 2015, , 69.	0.4	2

#	ARTICLE	IF	CITATIONS
249	Morning Stiffness in Rheumatoid Arthritis: Investigating its Relationship with Disease Activity as Assessed by Power Doppler Ultrasonography and Composite Scores. <i>Myopain</i> , 2015, 23, 182-187.	0.0	0
250	Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0122088.	1.1	33
251	Pain Sensitisation in Women with Active Rheumatoid Arthritis: A Comparative Cross-Sectional Study. <i>Arthritis</i> , 2015, 2015, 1-5.	2.0	33
252	The Role of Power Doppler Ultrasonography as Disease Activity Marker in Rheumatoid Arthritis. <i>Disease Markers</i> , 2015, 2015, 1-9.	0.6	37
253	Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice. <i>Rheumatology</i> , 2015, 54, 959-961.	0.9	20
254	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	0.9	51
255	Persistence of subclinical sonographic joint activity in rheumatoid arthritis in sustained clinical remission. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2050-2053.	0.5	15
256	Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. <i>Rheumatology</i> , 2015, 54, 2205-2214.	0.9	14
258	Structural integrity versus radiographic progression in rheumatoid arthritis: Figure 1. <i>RMD Open</i> , 2015, 1, e000064.	1.8	10
259	Validation of RAPID3 using a Japanese version of Multidimensional Health Assessment Questionnaire with Japanese rheumatoid arthritis patients: Characteristics of RAPID3 compared to DAS28 and CDAI. <i>Modern Rheumatology</i> , 2015, 25, 264-269.	0.9	8
260	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 3-9.	0.5	125
261	Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. <i>Rheumatology International</i> , 2015, 35, 1193-1210.	1.5	14
263	Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis - Yes. <i>Multiple Sclerosis Journal</i> , 2015, 21, 134-136.	1.4	7
264	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	3.5	372
265	Ras Guanine Nucleotide Releasing Protein 4 Is Aberrantly Expressed in the Fibroblast-like Synoviocytes of Patients With Rheumatoid Arthritis and Controls Their Proliferation. <i>Arthritis and Rheumatology</i> , 2015, 67, 396-407.	2.9	16
266	A Randomized, Double-blind, Placebo-controlled, Twelve-week, Dose-ranging Study of Decernotinib, an Oral Selective JAK3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 334-343.	2.9	98
267	Randomized clinical trials as reflexive interpretative process in patients with rheumatoid arthritis: a qualitative study. <i>Rheumatology International</i> , 2015, 35, 1423-1430.	1.5	4
268	Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. <i>Osteoporosis International</i> , 2015, 26, 961-968.	1.3	42

#	ARTICLE	IF	CITATIONS
269	Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study. <i>Rheumatology International</i> , 2015, 35, 759-763.	1.5	5
270	Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 741-748.	1.0	8
271	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies—a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 411-423.	0.8	23
272	IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 18-27.	1.6	32
273	Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 441-449.	1.0	48
274	Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 959-965.	0.8	21
275	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
276	Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. <i>Value in Health</i> , 2015, 18, 817-823.	0.1	8
277	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1107-1123.	1.6	84
278	2014 treat-to-target RA recommendations strategy is key. <i>Nature Reviews Rheumatology</i> , 2015, 11, 509-511.	3.5	14
279	Iguratimod for the treatment of rheumatoid arthritis in Japan. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 565-573.	1.3	37
280	Remission in rheumatoid arthritis: is it all the same?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 575-586.	1.3	11
281	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 777-788.	1.1	4
282	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	8.2	14
284	Factors Associated With Sustained Remission in Patients With Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 237-241.	0.2	3
285	Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 724-729.	0.5	52
287	Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials. <i>Current Rheumatology Reports</i> , 2015, 17, 28.	2.1	60
289	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	1.6	49

#	ARTICLE	IF	CITATIONS
290	Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 34.	1.6	22
291	Effect of Smoking on Remission Proportions Differs Between Male and Female Patients with Rheumatoid Arthritis: A Study Based on the IORRA Survey. <i>Journal of Rheumatology</i> , 2015, 42, 1083-1089.	1.0	12
292	Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study. <i>Modern Rheumatology</i> , 2015, 25, 831-836.	0.9	9
293	Psychological state is related to the remission of the Boolean-based definition of patient global assessment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015, 25, 679-682.	0.9	10
295	Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 117.	1.6	59
296	Brief Report: Leucine- ² -Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2056-2060.	2.9	71
297	Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations. <i>Journal of Rheumatology</i> , 2015, 42, 952-959.	1.0	14
298	Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus. <i>Drugs in R and D</i> , 2015, 15, 307-317.	1.1	10
299	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 279-294.	0.2	38
300	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
301	Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. <i>Reumatología Clínica</i> , 2015, 11, 279-294.	0.2	89
302	Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2015, 17, 219.	1.6	56
303	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	0.9	23
304	Patient-reported outcomes in core domain sets for rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 705-712.	3.5	45
305	Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. <i>Journal of Rheumatology</i> , 2015, 42, 2029-2037.	1.0	39
306	Factores asociados a remisión sostenida en pacientes con artritis reumatoide. <i>Reumatología Clínica</i> , 2015, 11, 237-241.	0.2	4
307	Toward Treating to Target in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 14-16.	2.2	2
309	Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. <i>Clinical Rheumatology</i> , 2015, 34, 221-230.	1.0	22

#	ARTICLE	IF	CITATIONS
310	Disease activity and left ventricular structure in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 511-519.	0.9	27
311	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291.	0.9	22
312	Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. <i>Translational Research</i> , 2015, 165, 270-282.	2.2	120
313	Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study. <i>Archives of Rheumatology</i> , 2016, 31, 127-132.	0.3	0
314	Current concepts in the management of rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 210-218.	0.7	67
315	Evidence from a Multidimensional Health Assessment Questionnaire (MDHAQ) of the Value of a Biopsychosocial Model to Complement a Traditional Biomedical Model in Care of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 212.	0.4	1
316	Recent Trends of Ultrasound in Rheumatology. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 11.	0.4	0
317	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. <i>Journal of Korean Medical Science</i> , 2016, 31, 1907.	1.1	7
318	Changes in foot function, disease activity, and disability after forefoot resection arthroplasty in patients with rheumatoid arthritis. <i>Journal of Medical Investigation</i> , 2016, 63, 38-44.	0.2	2
319	Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1457-1471.	0.5	33
320	Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. <i>Arthritis Research and Therapy</i> , 2016, 18, 114.	1.6	49
321	Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?. <i>Arthritis and Rheumatology</i> , 2016, 68, 2061-2066.	2.9	7
322	Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. <i>Arthritis Care and Research</i> , 2016, 68, 1616-1623.	1.5	31
323	Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000270.	1.8	19
324	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1763-1769.	0.5	70
325	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000205.	1.8	15
326	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1043-1050.	0.5	167
327	Musculoskeletal ultrasound in rheumatology in Korea: targeted ultrasound initiative survey. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 335-342.	0.9	4

#	ARTICLE	IF	CITATIONS
328	Predictive factors of radiological progression after 2â€¦years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , 2016, 2, e000172.	1.8	13
329	Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 1959-1967.	0.9	7
330	Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2087-2094.	0.5	67
331	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. <i>RMD Open</i> , 2016, 2, e000210.	1.8	3
332	A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. <i>RMD Open</i> , 2016, 2, e000133.	1.8	40
333	Patient-Reported Outcomes in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 219-237.	0.8	29
334	Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naïve Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 699-706.	1.0	17
335	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. <i>Journal of Rheumatology</i> , 2016, 43, 1285-1291.	1.0	26
336	The Challenge and Opportunity of Capturing Patient Reported Measures of Rheumatoid Arthritis Disease Activity in Vulnerable Populations with Limited Health Literacy and Limited English Proficiency. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 347-362.	0.8	7
337	Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. <i>Journal of Medical Economics</i> , 2016, 19, 812-821.	1.0	9
338	Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 227.	1.6	90
339	Validity of Doppler subclinical synovitis as an activity marker associated with bone erosions in rheumatoid arthritis patients during clinical remission. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2016, 47, 985-990.	0.3	2
340	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1428-1437.	0.5	232
341	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1718-1723.	1.0	16
342	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1216-1225.	0.9	26
343	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 107-118.	1.2	21
344	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	1.5	27
345	Efficacy and Safety of Subcutaneous Golimumab in Methotrexateâ€Naïve Patients With Rheumatoid Arthritis: Fiveâ€Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016, 68, 744-752.	1.5	32

#	ARTICLE	IF	CITATIONS
346	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1-25.	1.5	890
347	Using Dermal Temperature to Identify Rheumatoid Arthritis Patients With Radiologic Progressive Disease in Less Than One Minute. Arthritis Care and Research, 2016, 68, 1201-1205.	1.5	6
348	A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; <sc>ZRC</sc> 197) and adalimumab (Humira) in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2016, 19, 1157-1168.	0.9	57
349	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1-26.	2.9	1,880
350	Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskeletal Disorders, 2016, 17, 358.	0.8	8
351	ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 1631-1636.	1.0	8
352	Diagnosis and management of rheumatoid arthritis; What is the current role of established and new imaging techniques in clinical practice?. Best Practice and Research in Clinical Rheumatology, 2016, 30, 586-607.	1.4	20
354	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 2016, 18, 260.	1.6	44
355	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Research and Therapy, 2016, 18, 251.	1.6	177
356	Varus thrust in women with early medial knee osteoarthritis and its relation with the external knee adduction moment. Clinical Biomechanics, 2016, 39, 109-114.	0.5	29
357	Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls. Lupus Science and Medicine, 2016, 3, e000189.	1.1	9
358	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ, The, 2016, 354, i4205.	3.0	200
359	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	0.8	22
360	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. Arthritis Research and Therapy, 2016, 18, 115.	1.6	30
361	Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Research and Therapy, 2016, 18, 23.	1.6	37
362	Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clinica Chimica Acta, 2016, 459, 177-186.	0.5	66
363	The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 560-565.	0.5	148
364	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology, 2016, 55, 640-648.	0.9	29

#	ARTICLE	IF	CITATIONS
365	Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission?. <i>Rheumatology International</i> , 2016, 36, 387-396.	1.5	11
366	Changes in proprioceptive weighting during quiet standing in women with early and established knee osteoarthritis compared to healthy controls. <i>Gait and Posture</i> , 2016, 44, 184-188.	0.6	10
367	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. <i>Journal of Rheumatology</i> , 2016, 43, 298-306.	1.0	37
368	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , 2016, 55, 1177-1187.	0.9	31
369	Peroxisome proliferator-activated receptor gamma expression in peripheral monocytes from rheumatoid arthritis patients. <i>Egyptian Rheumatologist</i> , 2016, 38, 141-146.	0.5	1
370	Management of rheumatoid arthritis: what happens and what does not happen in real life. <i>Rheumatology International</i> , 2016, 36, 167-168.	1.5	2
371	Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group. <i>Modern Rheumatology</i> , 2016, 26, 828-835.	0.9	15
372	Iguratimod in combination with methotrexate in active rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 2016, 75, 828-833.	0.5	28
373	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1321-1327.	0.5	42
374	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. <i>Modern Rheumatology</i> , 2016, 26, 481-490.	0.9	13
375	Signs of forefeet joint synovitis have a limited impact on patient's perception of rheumatoid arthritis disease activity and acute-phase reactants. <i>Modern Rheumatology</i> , 2016, 26, 200-205.	0.9	4
376	Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1637-1644.	0.5	73
377	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.5	63
378	Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 141-146.	0.9	58
379	Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 879-885.	1.0	13
380	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.5	146
382	Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1143-1148.	1.0	26
383	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD012591.	1.5	44

#	ARTICLE	IF	CITATIONS
384	Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. <i>Rheumatology International</i> , 2017, 37, 799-806.	1.5	37
385	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 96-104.	0.5	86
386	Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 7.	0.4	3
387	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
388	Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response. <i>Modern Rheumatology</i> , 2017, 27, 961-966.	0.9	6
389	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. <i>Rheumatology</i> , 2017, 56, 1293-1301.	0.9	19
390	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. <i>Trials</i> , 2017, 18, 161.	0.7	19
391	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	2.9	39
392	Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 147-153.	1.0	7
393	What the Rheumatologist Is Looking for and What the Radiologist Should Know in Imaging for Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , 2017, 55, 905-916.	0.9	7
394	Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e12-e12.	0.5	6
395	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
396	Dynamic and static knee alignment at baseline predict structural abnormalities on MRI associated with medial compartment knee osteoarthritis after 2 years. <i>Gait and Posture</i> , 2017, 57, 46-51.	0.6	12
397	Abatacept: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2017, 77, 1221-1233.	4.9	143
398	Efficacy and Safety of GuiZhi-ShaoYao-ZhiMu Decoction for Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 756-770.	2.1	28
399	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	2.9	52
400	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 792-801.	0.5	92
401	A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 1347-1356.	1.5	7

#	ARTICLE	IF	CITATIONS
402	Fatigue in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 25.	2.1	64
403	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 57-69.	1.1	11
404	Determining the acceptable level of physician compliance with a treatment target strategy in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 576-583.	0.9	7
406	A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis. <i>Immunotherapy</i> , 2017, 9, 1133-1142.	1.0	5
407	Evaluation of the activity of rheumatoid arthritis in clinical practice. Agreement between self-rated clinimetric evaluation and clinical evaluation with activity indexes: DAS28, CDAI and SDAI. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 293-299.	0.1	1
408	Ávaluación de la actividad de la polyarthritis reumatoide. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 343-346.	0.0	0
409	Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 249-262.	1.2	88
410	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
411	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	0.9	49
412	Remission "keeping the patient experience front and centre. <i>Nature Reviews Rheumatology</i> , 2017, 13, 573-574.	3.5	11
413	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. <i>The Cochrane Library</i> , 2017, 2017, CD007649.	1.5	40
414	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017, 16, 1119-1124.	2.5	13
415	The outcomes of haemophilia and its treatment: why we need a core set. <i>Haemophilia</i> , 2017, 23, 485-487.	1.0	3
416	Evaluación de la actividad de la artritis reumatoide en la atención clínica habitual. Concordancia entre la autoclínimétrica y la evaluación clínica con los Índices de actividad: DAS28, CDAI y SDAI. <i>Medicina Clínica</i> , 2017, 149, 293-299.	0.3	6
417	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 371-393.	2.9	52
418	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	1.0	15
419	Preventing disability in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 865-876.	1.4	27
420	Discordant patient-physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000551.	1.8	17

#	ARTICLE	IF	CITATIONS
421	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017, 56, 1586-1596.	0.9	20
422	Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 163.	0.8	36
423	Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies. <i>Arthritis Research and Therapy</i> , 2017, 19, 90.	1.6	10
424	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
425	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	2.9	24
426	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , 2017, 69, 518-528.	2.9	23
427	Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. <i>Arthritis Care and Research</i> , 2017, 69, 609-615.	1.5	11
428	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017, 69, 783-793.	1.5	32
429	Fármacos biosimilares: un nuevo escenario en las terapias biológicas. <i>Reumatología Clínica</i> , 2017, 13, 287-293.	0.2	3
430	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017, 69, 989-996.	1.5	8
431	Biosimilars: A New Scenario in Biologic Therapies. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 287-293.	0.2	3
432	Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study. <i>Rheumatology</i> , 2017, 56, 2154-2161.	0.9	18
433	Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. <i>RMD Open</i> , 2017, 3, e000538.	1.8	18
434	Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1193-1200.	0.9	18
435	Comparison of the Disease Activity Score-28 Based on the Erythrocyte Sedimentation Rate and C-reactive Protein in Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2017, 24, 287.	0.4	7
436	High Disease Activity May Increase Fear-Avoidance Beliefs in Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2017, 32, 325-332.	0.3	4
437	The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. <i>Journal of Intercultural Ethnopharmacology</i> , 2017, 6, 58.	0.9	7
438	Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 131-138.	0.8	14

#	ARTICLE	IF	CITATIONS
439	Patient's perspective of sustained remission in rheumatoid arthritis. BMC Musculoskeletal Disorders, 2017, 18, 379.	0.8	2
440	Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes, 2017, 15, 237.	1.0	1
441	Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes, 2017, 15, 239.	1.0	8
442	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials, 2017, 18, 591.	0.7	14
443	Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Research and Therapy, 2017, 19, 155.	1.6	55
444	A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA [®]) to the reference product (Humira [®]) in patients with active rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 168.	1.6	26
445	Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study. Arthritis Research and Therapy, 2017, 19, 221.	1.6	29
446	Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. BMC Research Notes, 2017, 10, 765.	0.6	7
447	Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis. PeerJ, 2017, 5, e4035.	0.9	30
448	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. Reumatologia, 2017, 55, 284-289.	0.5	6
449	Treatment of Rheumatoid Arthritis. , 2017, , 1187-1212.e5.		0
450	Rheumatoid Arthritis Comorbidity Index (RACI): Development and Validation of a New Comorbidity Index for Rheumatoid Arthritis Patients. Journal of Arthritis, 2017, 06, .	0.3	2
451	Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Internal Medicine, 2017, 56, 1147-1152.	0.3	3
452	Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study. Clinical Rheumatology, 2018, 37, 1449-1455.	1.0	2
453	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. Clinical Rheumatology, 2018, 37, 1503-1510.	1.0	13
454	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. Rheumatology and Therapy, 2018, 5, 43-55.	1.1	4
455	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical Rheumatology, 2018, 37, 2043-2053.	1.0	9
456	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clinical Rheumatology, 2018, 37, 2055-2062.	1.0	23

#	ARTICLE	IF	CITATIONS
457	Rheumatoid Arthritis Magnetic Resonance Imaging Score Predicts Therapy Response: Results of the German ArthroMark Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 753-759.	1.0	3
458	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. <i>Clinical Immunology</i> , 2018, 191, 67-74.	1.4	12
459	Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab. <i>Arthritis and Rheumatology</i> , 2018, 70, 1200-1208.	2.9	39
460	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212934.	0.5	19
461	Outcomes of Resection and Joint-Preserving Arthroplasty for Forefoot Deformities for Rheumatoid Arthritis. <i>Foot and Ankle International</i> , 2018, 39, 292-299.	1.1	20
462	Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review. <i>Arthritis Care and Research</i> , 2018, 70, 1501-1508.	1.5	28
463	The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 329-334.	1.0	1
464	Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. <i>Modern Rheumatology</i> , 2018, 28, 950-959.	0.9	14
465	Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Modern Rheumatology</i> , 2018, 28, 789-799.	0.9	59
466	Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 901-908.	1.0	11
467	Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 673-687.	0.9	6
469	High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 538-546.	1.6	20
470	The controversy of using PGA to define remission in RA. <i>Nature Reviews Rheumatology</i> , 2018, 14, 245-245.	3.5	1
471	Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 935-947.	1.5	89
472	Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212245.	0.5	88
473	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 197-204.	1.5	65
474	Development and testing of candidate items for inclusion in a new rheumatoid arthritis stiffness patient-reported outcome measure. <i>Rheumatology</i> , 2018, 57, 263-272.	0.9	10
475	Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial. <i>Joint Bone Spine</i> , 2018, 85, 59-64.	0.8	15

#	ARTICLE	IF	CITATIONS
476	Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2018, 70, 205-212.	1.5	34
477	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	1.5	84
478	Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. <i>Modern Rheumatology</i> , 2018, 28, 48-57.	0.9	18
479	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	1.6	9
480	Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. <i>Arthritis Care and Research</i> , 2018, 70, 861-868.	1.5	17
481	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , 2018, 28, 770-779.	0.9	5
482	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. <i>Clinical Rheumatology</i> , 2018, 37, 597-605.	1.0	21
483	Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy. <i>Modern Rheumatology</i> , 2018, 28, 235-241.	0.9	0
484	Reply. <i>Arthritis Care and Research</i> , 2018, 70, 958-959.	1.5	0
485	Role of Pyridines in Medicinal Chemistry and Design of BACE1 Inhibitors Possessing a Pyridine Scaffold. , 0, , .		31
487	Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results. <i>Biologics: Targets and Therapy</i> , 2018, Volume 12, 171-182.	3.0	6
488	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Various Biologic DMARDs. <i>Frontiers in Pharmacology</i> , 2018, 9, 1303.	1.6	7
489	DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2018, 4, e000765.	1.8	14
490	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	1.8	9
491	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1070.	1.6	30
492	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
493	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 275-284.	0.7	14
494	A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in rheumatoid arthritis. <i>Libyan Journal of Medicine</i> , 2018, 13, 1512330.	0.8	11

#	ARTICLE	IF	CITATIONS
495	Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis. <i>BMC Rheumatology</i> , 2018, 2, 16.	0.6	7
496	Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. <i>Quality of Life Research</i> , 2018, 27, 2443-2451.	1.5	17
497	Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study. <i>Journal of Rheumatology</i> , 2018, 45, 1229-1239.	1.0	14
499	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	1.6	22
500	Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities. <i>Frontiers in Physiology</i> , 2018, 9, 176.	1.3	5
501	2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. <i>Advances in Rheumatology</i> , 2018, 58, 2.	0.8	25
502	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. <i>Rheumatology</i> , 2018, 57, 2022-2031.	0.9	19
503	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. <i>Quality of Life Research</i> , 2018, 27, 2909-2921.	1.5	8
504	Goals of gout treatment: a patient perspective. <i>Clinical Rheumatology</i> , 2018, 37, 2557-2566.	1.0	8
505	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2018, 20, 160.	1.6	16
506	Superb microvascular imaging (SMI) for evaluating hand joint lesions in patients with rheumatoid arthritis in clinical remission. <i>Rheumatology International</i> , 2018, 38, 1885-1890.	1.5	27
507	Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF- κ B Ligand-Induced Osteoclast Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 234.	2.2	18
508	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018, 5, 40.	1.2	26
509	The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 146.	1.6	18
510	Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity. <i>RMD Open</i> , 2018, 4, e000695.	1.8	6
511	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	1.6	29
512	Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2018, 38, 7.	1.5	17
513	Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 374-383.	1.6	13

#	ARTICLE	IF	CITATIONS
514	Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2018, 2, 8.	0.6	28
515	Musculoskeletal ultrasound for predicting remission in patients with rheumatoid arthritis: results from a 1-year prospective study. <i>Rheumatology International</i> , 2018, 38, 1891-1899.	1.5	6
516	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
517	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. <i>Frontiers in Medicine</i> , 2018, 5, 140.	1.2	7
518	Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000649.	1.8	7
519	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1391-1393.	0.5	5
520	Reduction of Articular and Systemic Inflammation by Kava-241 in a <i>Porphyromonas gingivalis</i> -Induced Arthritis Murine Model. <i>Infection and Immunity</i> , 2018, 86, .	1.0	16
521	Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF- κ B and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two yearsâ€™ treatment for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2019, 29, 418-429.	0.9	18
522	Performance of serum adenosine deaminase in measuring disease activity in rheumatoid arthritis patients. <i>Egyptian Rheumatologist</i> , 2019, 41, 81-85.	0.5	8
523	Limited Health Literacy and Patient Confusion About Rheumatoid Arthritis Patient Global Assessments and Model Disease States. <i>Arthritis Care and Research</i> , 2019, 71, 611-619.	1.5	27
524	The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. <i>Pharmacoeconomics</i> , 2019, 37, 75-84.	1.7	22
525	Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. <i>Rheumatology</i> , 2020, 59, 613-621.	0.9	14
526	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 14.	0.9	33
527	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	0.7	77
528	The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. <i>BMC Rheumatology</i> , 2019, 3, 25.	0.6	3
529	Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. <i>Clinical Rheumatology</i> , 2019, 38, 3049-3059.	1.0	3
531	Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1670-1678.	0.9	8
532	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. <i>Journal of Autoimmunity</i> , 2019, 105, 102298.	3.0	34

#	ARTICLE	IF	CITATIONS
533	Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. Chinese Medical Journal, 2019, 132, 1009-1014.	0.9	10
534	Predictors and the optimal duration of sustained remission in rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 3033-3039.	1.0	5
535	<p>A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis â€œ results of clinical relevance</p>. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 207-217.	0.8	19
536	An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance. Frontiers in Endocrinology, 2019, 10, 729.	1.5	17
537	The â€œTreat to Targetâ€ Approach to Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2019, 45, 487-504.	0.8	17
538	Subclinical Treatment Targets in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, 593-604.	0.8	3
539	A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatology, 2019, 3, 42.	0.6	50
540	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatology, The, 2019, 1, e23-e34.	2.2	25
541	Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. BMC Musculoskeletal Disorders, 2019, 20, 420.	0.8	11
542	Precision medicine in rheumatoid arthritis: are we there yet?. Clinical Rheumatology, 2019, 38, 2965-2966.	1.0	2
543	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Fourâ€ Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	2.9	64
544	Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity. RMD Open, 2019, 5, e000912.	1.8	16
546	Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. Annals of the Rheumatic Diseases, 2019, 78, 1333-1338.	0.5	15
547	Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?. Journal of Rheumatology, 2019, 46, 443-446.	1.0	8
548	Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. Arthritis Research and Therapy, 2019, 21, 115.	1.6	7
549	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 116.	1.6	23
550	Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-Î³ autoantibodies. PLoS ONE, 2019, 14, e0215581.	1.1	25
551	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. European Journal of Internal Medicine, 2019, 66, 57-61.	1.0	9

#	ARTICLE	IF	CITATIONS
552	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?â€”MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	1.0	54
554	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. <i>RMD Open</i> , 2019, 5, e000840.	1.8	8
555	The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 100.	1.6	19
556	The superb microvascular imaging is more sensitive than conventional power Doppler imaging in detection of active synovitis in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2613-2620.	1.0	21
557	Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. <i>Trials</i> , 2019, 20, 226.	0.7	3
558	Ultrasound imaging in rheumatoid arthritis. <i>Radiologia Medica</i> , 2019, 124, 1087-1100.	4.7	59
560	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. <i>BioDrugs</i> , 2019, 33, 79-91.	2.2	26
561	MR and ultrasound of the hands and wrists in rheumatoid arthritis. Part II. Added clinical value. <i>Skeletal Radiology</i> , 2019, 48, 837-857.	1.2	12
562	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2019, 71, 1300-1303.	1.5	5
563	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	1.5	41
564	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 1483-1493.	0.9	18
565	Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study. <i>BMJ Open</i> , 2019, 9, e031467.	0.8	8
566	General Orthopaedic Roundtable: Workup of Recurrent Knee Effusions in a 57-Year-Old Male with Mild Knee Arthritis. <i>JBJS Journal of Orthopaedics for Physician Assistants</i> , 2019, 7, e0050.	0.0	0
567	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2019, , .	1.5	0
568	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. <i>RMD Open</i> , 2019, 5, e001050.	1.8	14
569	Baricitinib for rheumatoid arthritis. <i>The Cochrane Library</i> , 2019, , .	1.5	2
570	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2019, 2019, CD010455.	1.5	33
571	Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	1.4	22

#	ARTICLE	IF	CITATIONS
572	Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research. <i>PLoS ONE</i> , 2019, 14, e0215192.	1.1	17
573	Effectiveness of non-pharmacological and non-surgical interventions on the impact of rheumatoid arthritis. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 22-27.	1.7	4
574	Rheumatoid arthritis in remission. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 1-7.	1.0	17
575	2-D speckle-tracking assessment of left and right ventricular function in rheumatoid arthritis patients with and without disease activity. <i>Journal of the Saudi Heart Association</i> , 2019, 31, 41-49.	0.2	10
576	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	0.9	16
577	Evaluation of the effect of foot disease activity on Boolean remission in Japanese patients with rheumatoid arthritis: A cross-sectional study. <i>Musculoskeletal Care</i> , 2019, 17, 152-155.	0.6	0
578	Validity of 7-Joint Versus Simplified 12-Joint Ultrasonography Scoring Systems in Assessment of Rheumatoid Arthritis Activity. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 264-271.	0.5	7
579	Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. <i>Arthritis Care and Research</i> , 2020, 72, 27-35.	1.5	27
580	Estimating Optimal Dynamic Treatment Regimes With Survival Outcomes. <i>Journal of the American Statistical Association</i> , 2020, 115, 1531-1539.	1.8	27
581	Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 326-333.	1.5	19
582	Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. <i>Rheumatology</i> , 2020, 59, 1272-1280.	0.9	17
583	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	1.6	25
584	Prediction of recurrence and remission using superb microvascular imaging in rheumatoid arthritis. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 131-138.	0.6	6
585	Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. <i>Modern Rheumatology</i> , 2020, 30, 1009-1015.	0.9	4
586	Drug-Using Behaviors of Turkish Armed Forces Service Members: A Social Control Perspective. <i>Military Behavioral Health</i> , 2020, 8, 222-231.	0.4	2
587	How do neuropathic pain-like symptoms affect health-related quality of life among patients with rheumatoid arthritis?: A comparison of multiple pain-related parameters. <i>Modern Rheumatology</i> , 2020, 30, 828-834.	0.9	5
588	Muscle stiffness in rheumatoid arthritis is not altered or associated with muscle weakness: A shear wave elastography study. <i>Modern Rheumatology</i> , 2020, 30, 617-625.	0.9	9
589	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164.	0.9	21

#	ARTICLE	IF	CITATIONS
590	A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options. <i>Modern Rheumatology</i> , 2020, 30, 1-6.	0.9	83
591	Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 132-140.	0.5	4
592	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020, 59, 1556-1565.	0.9	9
593	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	0.9	8
594	Shared decision-making in people with chronic disease: Integrating the biological, social and lived experiences is a key responsibility of nurses. <i>Musculoskeletal Care</i> , 2020, 18, 84-91.	0.6	8
595	A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 65.	1.8	35
596	Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2381-2391.	0.9	10
597	Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1676-1684.	0.9	46
598	Value of Platelet Distribution Width and Mean Platelet Volume in Disease Activity Score of Rheumatoid Arthritis. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 595-606.	1.6	11
599	Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. <i>Network and Systems Medicine</i> , 2020, 3, 91-104.	2.7	26
600	Measures of Rheumatoid Arthritis Disease Activity. <i>Arthritis Care and Research</i> , 2020, 72, 4-26.	1.5	9
601	Contemporary imaging of rheumatoid arthritis: Clinical role of ultrasound and MRI. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101593.	1.4	18
602	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1407-1408.	2.9	0
603	Measurement of overall perceived health using different scales in patients with rheumatoid arthritis: a proposal of a combined scale. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 262-268.	0.1	0
604	Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. <i>BMJ</i> , The, 2020, 371, m4328.	3.0	50
605	Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2020, 10, 220.	1.1	6
606	Medición de la percepción global de salud mediante diferentes escalas en pacientes con artritis reumatoide: propuesta de una escala combinada. <i>Revista Colombiana De Reumatología</i> , 2020, 27, 262-268.	0.0	0
607	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , 2020, 10, 18634.	1.6	15

#	ARTICLE	IF	CITATIONS
608	The impact of functional medicine on patient-reported outcomes in inflammatory arthritis: A retrospective study. PLoS ONE, 2020, 15, e0240416.	1.1	6
609	Rheumatoid arthritis. Inflammation and Regeneration, 2020, 40, 20.	1.5	52
610	Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 196.	1.6	9
611	A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition. ACR Open Rheumatology, 2020, 2, 301-306.	0.9	1
612	Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2020, 72, 1621-1631.	2.9	55
613	A new laboratory surrogate (Monocyte Chemotactic Protein-1) for Disease Activity Score ₂₈ : a favourable indicator for remission in rheumatoid arthritis. Scientific Reports, 2020, 10, 8238.	1.6	5
614	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. Rheumatology, 2020, 59, 3458-3467.	0.9	6
615	Cumulative patient-based disease activity monitoring in rheumatoid arthritis " predicts sustained remission, flare and treatment escalation. Seminars in Arthritis and Rheumatism, 2020, 50, 749-758.	1.6	1
616	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2091532.	1.2	6
617	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 2020, 6, e001096.	1.8	3
618	Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). Joint Bone Spine, 2020, 87, 307-313.	0.8	4
619	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Annals of the Rheumatic Diseases, 2020, 79, 464-471.	0.5	14
620	Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study. Chinese Medical Journal, 2020, 133, 1397-1403.	0.9	2
621	Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ, The, 2020, 370, m2288.	3.0	39
622	Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero™s adalimumab (Mabura®), Tj ETQq0 0 0 rgBT /Overlo rheumatoid arthritis on concomitant methotrexate therapy. BMC Rheumatology, 2020, 4, 24.	0.6	5
623	A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 158.	1.6	20
624	Association of a Type 2 "Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2020, 72, 1091-1102.	2.9	8
625	Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-Target Strategies. Arthritis and Rheumatology, 2020, 72, 1072-1081.	2.9	7

#	ARTICLE	IF	CITATIONS
626	Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 370-384.	0.8	22
627	Benefits and applications of microwave-assisted synthesis of nitrogen containing heterocycles in medicinal chemistry. <i>RSC Advances</i> , 2020, 10, 14170-14197.	1.7	133
628	Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 983-989.	1.5	8
629	Classifying Remission in Rheumatoid Arthritis Treatâ€œâ€Target Studies: Comment on the Article by Norvang et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1406-1407.	2.9	0
630	Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study. <i>Modern Rheumatology</i> , 2021, 31, 101-107.	0.9	5
631	Predictors of longâ€œterm clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13363.	1.7	6
632	Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 1739-1749.	1.0	3
633	Traitement anti-TNF ou non anti-TNF dans la polyarthrite rhumatoÃˆde activeÂˆ: facteurs dÃ©terminant le choix des patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 49-55.	0.0	0
634	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
635	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. <i>Nature Reviews Rheumatology</i> , 2021, 17, 135-144.	3.5	49
636	The Relationship of Asthma Biologics to Remission for Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1090-1098.	2.0	33
637	Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110118.	1.2	9
638	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110090.	1.2	3
639	Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab004.	0.3	2
640	Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 83-84.	13.9	3
641	The number of risk factors for persistent disease determines the clinical course of early arthritis. <i>Rheumatology</i> , 2021, 60, 3617-3627.	0.9	3
642	Construct validity and response to therapy of the U9 ultrasonographic scale for assessment of disease activity in rheumatoid arthritis. <i>Reumatologia</i> , 2021, 59, 211-218.	0.5	1
643	Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110140.	1.2	6

#	ARTICLE	IF	CITATIONS
644	A Review on Rheumatoid Arthritis Interventions and Current Developments. <i>Current Drug Targets</i> , 2021, 22, 463-483.	1.0	8
645	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.2	9
646	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	1.6	13
647	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1130-1136.	0.5	33
648	Artritis reumatoide: Tratamiento. <i>Medicine</i> , 2021, 13, 1681-1693.	0.0	1
649	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1755.	3.8	17
650	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. <i>Rheumatology</i> , 2021, 60, 5073-5079.	0.9	12
651	Biomarkers in Rheumatoid Arthritis. <i>Cureus</i> , 2021, 13, e15063.	0.2	12
652	Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2021, 11, 573.	1.1	7
653	Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis. <i>Clinical Rheumatology</i> , 2021, 40, 3143-3151.	1.0	6
654	Proinflammatory Features of Stem Cell-like Memory T Cells from Human Patients with Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2021, 207, 381-388.	0.4	1
655	Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4527-4531.	1.0	10
656	Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). <i>RMD Open</i> , 2021, 7, e001673.	1.8	7
657	Association of health-related quality of life with self-management and satisfaction of relationship with healthcare professionals in female patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 114-120.	0.9	1
658	Interleukin-6 and Serum/Fecal Calprotectin as Useful Specific Markers for Monitoring Rheumatic Diseases: A Pilot Study. <i>Laboratory Medicine</i> , 2021, , .	0.8	1
659	Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220750.	0.5	12
660	Residual Pain in the Context of Selecting and Switching Biologic Therapy in Inflammatory Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 712645.	1.2	5
661	Dissociation between 2-[18F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission. <i>BMC Rheumatology</i> , 2021, 5, 31.	0.6	3

#	ARTICLE	IF	CITATIONS
662	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients Receiving Combination Therapy: Comment on the Article by Curtis et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 1771-1771.	2.9	1
663	Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021, 7, e001621.	1.8	10
664	Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 470-480.	0.6	8
665	Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission. <i>Sultan Qaboos University Medical Journal</i> , 2022, 22, 554-560.	0.3	2
666	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
667	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	1.6	41
668	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	1.5	20
669	Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab030.	0.3	5
670	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.5	123
672	Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. <i>Modern Rheumatology</i> , 2012, 22, 209-215.	0.9	6
673	Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. <i>Modern Rheumatology</i> , 2012, 22, 370-375.	0.9	14
674	A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. <i>Modern Rheumatology</i> , 2013, 23, 245-253.	0.9	6
675	Management of rheumatoid arthritis: the 2012 perspective. <i>Modern Rheumatology</i> , 2013, 23, 1-7.	0.9	32
676	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013, 23, 623-633.	0.9	23
677	How to Define Boolean Low Disease Activity in Rheumatoid Arthritis: Experience from a Large Real-world Cohort. <i>Rheumatology and Therapy</i> , 2021, 8, 289-301.	1.1	6
678	Clinical Features of Rheumatoid Arthritis. , 2013, , 1109-1136.e4.		10
679	Treatment of Rheumatoid Arthritis. , 2013, , 1137-1160.e4.		3
680	Evaluation and monitoring of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101480.	1.4	2

#	ARTICLE	IF	CITATIONS
681	Concepts in monitoring the treatment in rheumatoid arthritis – the role of musculoskeletal ultrasound. Part I: synovitis.. Medical Ultrasonography, 2015, 17, 367.	0.4	2
682	Tenosynovitis US scoring systems follow synovitis and clinical scoring systems in RA and are responsive to change after biologic therapy. Medical Ultrasonography, 2015, 17, 352.	0.4	14
683	Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Research, 2019, 8, 1549.	0.8	41
684	Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. F1000Research, 2016, 5, 2019.	0.8	4
685	Sapoin C Coupled Lipid Nanovesicles Specifically Target Arthritic Mouse Joints for Optical Imaging of Disease Severity. PLoS ONE, 2012, 7, e33966.	1.1	10
686	Copper Bracelets and Magnetic Wrist Straps for Rheumatoid Arthritis – Analgesic and Anti-Inflammatory Effects: A Randomised Double-Blind Placebo Controlled Crossover Trial. PLoS ONE, 2013, 8, e71529.	1.1	19
687	Further Optimization of the Reliability of the 28-Joint Disease Activity Score in Patients with Early Rheumatoid Arthritis. PLoS ONE, 2014, 9, e100544.	1.1	4
688	Serological and Progression Differences of Joint Destruction in the Wrist and the Feet in Rheumatoid Arthritis - A Cross-Sectional Cohort Study. PLoS ONE, 2015, 10, e0136611.	1.1	9
689	Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. PLoS ONE, 2016, 11, e0149141.	1.1	14
690	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0161727.	1.1	11
691	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF- α Inhibitors in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0163087.	1.1	43
692	Severity and Diurnal Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0166616.	1.1	10
693	Use of genetically engineered biological agents for the treatment of rheumatoid arthritis: general characteristics (a lecture). Nauchno-Prakticheskaya Revmatologiya, 2013, .	0.2	6
694	RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 263-271.	0.2	38
695	Rheumatoid arthritis: problems of treatment at the present stage. Sovremennaya Revmatologiya, 2018, 12, 65-70.	0.1	3
696	Rola ultrasonografii w diagnostyce chor ^{3b} reumatycznych w \AA wietle wytycznych ACR/EULAR. , 2016, 16, 55-64.		16
697	The Effect of Neuropathic Pain Symptoms on Remission in Patients with Early Rheumatoid Arthritis. Current Rheumatology Reviews, 2019, 15, 154-161.	0.4	18
698	Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region. Open Rheumatology Journal, 2016, 10, 13-25.	0.1	3

#	ARTICLE	IF	CITATIONS
699	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-258.	1.3	37
700	The ultrasound 7 score in the assessment of synovitis in rheumatoid arthritis: correlation with clinical disease activity indices. <i>Egyptian Rheumatology and Rehabilitation</i> , 2017, 44, 103-110.	0.2	6
701	Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience. <i>Swiss Medical Weekly</i> , 2013, 143, w13861.	0.8	25
702	Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?. <i>Annals of Dermatology</i> , 2019, 31, 495.	0.3	5
703	Is non-biological treatment of rheumatoid arthritis as good as biologics?. <i>World Journal of Orthopedics</i> , 2015, 6, 278.	0.8	13
704	Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X21110439.	1.2	6
705	Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e767-e777.	2.2	13
706	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. <i>European Respiratory Journal</i> , 2021, 58, 2102168.	3.1	8
708	Progress in the Treatment of Rheumatoid Arthritis and Decreasing Number of Patients Participating in Clinical Trials. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 42, 401-407.	0.1	0
709	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÄ¼ller-Ladner (Hrsg.): <i>Klinische Immunologie.</i> , 2012, , e1-e80.		0
711	Cytological examination of synovial fluid assessed in the diagnosis of rheumatoid arthritis and other related joint diseases. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2013, 52, 287-294.	0.0	1
712	Progress and Limitations in Treatment for Rheumatoid Arthritis with Biologics. <i>Spinal Surgery</i> , 2013, 27, 13-21.	0.0	0
713	Rheumatoid arthritisâ€™ clinical features. , 2013, , 858-866.		0
714	External Transdermal Procedures. , 2014, , 363-378.		0
715	Progression in the Treatment of Patients with Rheumatoid Arthritis and Changes in Surgical Treatment. <i>Journal of the Nihon University Medical Association</i> , 2014, 73, 140-144.	0.0	0
717	Evidence-Based Medicine in Rheumatology: How Does It Differ from Other Diseases?. , 2014, , 1-12.		0
718	Principles of clinical outcome assessment. , 2015, , 9-19.		10
720	Musculoskeletal ultrasonography in rheumatology. <i>Choonpa Igaku</i> , 2015, 42, 43-56.	0.0	0

#	ARTICLE	IF	CITATIONS
721	Clinical versus Ultrasound Examination to Detect Synovial Effusion of the Wrist in a Patient with Rheumatoid Arthritis. <i>Journal of Medical Diagnostic Methods</i> , 2015, 04, .	0.0	0
722	Rheumatoid Arthritis and Related Disorders. , 2015, , 1-20.		0
723	ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2015, 53, 522-541.	0.2	7
724	Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2015, 05, 104-112.	0.1	0
725	Assessment of Cytotoxicity and Genotoxicity in Patients with Rheumatoid Arthritis and its Relation to Disease Activity and Medications. <i>Egyptian Journal of Rheumatology and Clinical Immunology</i> , 2015, 3, 59-66.	0.0	0
726	Rheumatoid Arthritis and Related Disorders. , 2017, , 1525-1543.		0
727	Ultrasonographic findings of rheumatoid arthritis patients who are in clinical remission. <i>Journal of Research in Medical Sciences</i> , 2018, 23, 38.	0.4	4
728	Planning of a Clinical Data Registry for Basic Anti-Inflammatory Drugs for the Treatment of Rheumatoid Arthritis. <i>The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products</i> , 2018, 8, 238-245.	0.1	1
729	Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 56, 703-708.	0.2	1
731	Pigmented Villonodular Synovitis Developing in the Knee of a Rheumatoid Arthritis Patient Mistaken as a Rheumatoid Arthritis Flare-Up. <i>Korean Journal of Medicine</i> , 2019, 94, 133-136.	0.1	0
733	VIII. Patient Reported Outcome in Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 2124-2128.	0.0	0
735	Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 145.	0.3	0
736	Inflammatory Arthritis: Rheumatoid Arthritis. , 2020, , 676-688.		0
737	Obesity and Remission Rates in Japanese Patients With Rheumatoid Arthritis Requiring Anti-Tumor Necrosis Factor Alpha Therapy. <i>Archives of Rheumatology</i> , 2020, 35, 600-608.	0.3	1
738	Rheumatoid Arthritis and Related Disorders. , 2020, , 1-20.		0
739	Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 384.	0.3	2
740	Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 231-239.	0.7	1
741	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 163.	0.3	1

#	ARTICLE	IF	CITATIONS
744	The Adequacy of Evaluation by Rheumatologists before Undergoing Arthroscopic Synovectomy in Rheumatoid Arthritis Patients. <i>Archives of Hand and Microsurgery</i> , 2020, 25, 2-7.	0.1	0
745	Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naïve patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 824-830.	0.9	3
746	Shorter disease duration is important for tocilizumab to achieve Boolean remission. <i>Modern Rheumatology</i> , 2013, 23, 1192-7.	0.9	3
747	Meridian-sinew release therapy for the treatment of refractory rheumatoid arthritis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 8485-96.	1.3	0
748	Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. <i>International Ophthalmology</i> , 2022, 42, 689-711.	0.6	9
749	Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 778480.	2.2	3
750	Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab087.	0.3	4
751	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-eight Joint Disease Activity Score, C-reactive Protein Level, and Patient Global Assessment. <i>Arthritis Care and Research</i> , 2022, 74, 1-5.	1.5	3
752	Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review. <i>Advances in Therapy</i> , 2022, 39, 75-93.	1.3	4
753	Surgical treatment of wrist joint dysfunction in rheumatoid arthritis: A report of two cases. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.3	1
754	Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>RMD Open</i> , 2021, 7, e002034.	1.8	7
755	Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. <i>Rheumatology and Therapy</i> , 2022, 9, 175-189.	1.1	2
756	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-eight Joint Disease Activity Score, C-reactive Protein Level, and Patient Global Assessment. <i>Arthritis and Rheumatology</i> , 2022, 74, 5-9.	2.9	4
757	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C-reactive Protein, and Patient Global Assessment. <i>ACR Open Rheumatology</i> , 2022, 4, 123-127.	0.9	5
758	Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 4-7.	0.5	7
759	Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 223-241.	1.1	3
760	Challenges in Applying Treat to Target Strategy in Sample of Iraqi Patients with Rheumatoid Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 331.	0.3	1
761	Rheumatoid Arthritis and Related Disorders. , 2022, , 1615-1634.		0

#	ARTICLE	IF	CITATIONS
762	Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. <i>RMD Open</i> , 2022, 8, e002013.	1.8	4
763	Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. <i>Clinical Rheumatology</i> , 2022, 41, 1247-1254.	1.0	6
764	Sjögren's syndrome associated with erosive rheumatoid arthritis alters its prognosis and long-term therapeutic response: a case-control study. <i>Rheumatology International</i> , 2022, , 1.	1.5	0
765	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level and patient global assessment" by Felson et al. <i>ACR Open Rheumatology</i> , 2022, 4, 271-272.	0.9	1
766	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level, and patient global assessment: comment on the article by Felson et al. <i>Arthritis Care and Research</i> , 2022, 74, 501-502.	1.5	0
767	Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?. <i>Biochemical Pharmacology</i> , 2022, 197, 114929.	2.0	14
768	The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 839206.	1.2	1
769	Efficacy and Safety of Tripterygium Glycosides (TG) in Treating Rheumatoid Arthritis: An Updated Meta-Analysis of Thirty-Six Randomized Controlled Trials of TG Combined With One Kind of Conventional Disease-Modifying Anti-Rheumatic Drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
770	Validity and risk of adopting PGA ² as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, 2978.	1.6	1
771	Oral and Intestinal Bacterial Substances Associated with Disease Activities in Patients with Rheumatoid Arthritis: A Cross-Sectional Clinical Study. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	12
772	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. <i>Arthritis Research and Therapy</i> , 2022, 24, 47.	1.6	7
773	Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. <i>Advances in Therapy</i> , 2022, 39, 2065-2084.	1.3	47
774	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	1.1	9
775	Treating-to-target in rheumatology: Theory and practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101735.	1.4	12
776	Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 89-97.	0.4	1
777	Superb microvascular imaging is as sensitive as contrast-enhanced ultrasound for detecting synovial vascularity in rheumatoid arthritis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 2866-2876.	1.1	5
778	Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 729681.	2.2	4
779	Regulatory and other rheumatoid factors in rheumatoid arthritis patients with active disease or in remission. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24187.	0.9	1

#	ARTICLE	IF	CITATIONS
780	The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkab095.	0.3	10
781	Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review. <i>Healthcare (Switzerland)</i> , 2021, 9, 1726.	1.0	4
782	Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis. <i>ReumatologĀa ClĀnica</i> , 2021, , .	0.2	0
784	Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoĀ, SzopiĀ, ska</i> , 2022, 22, 21-27.	0.7	1
785	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. <i>Rheumatology</i> , 2022, 62, 116-123.	0.9	1
786	Musculoskeletal ultrasound for treating rheumatoid arthritis to targetĀa systematic literature review. <i>Rheumatology</i> , 2022, 61, 4590-4602.	0.9	4
787	Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. <i>EBioMedicine</i> , 2022, 80, 104053.	2.7	9
788	Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210963.	1.2	1
789	The Efficacy of <sc>ShortĀTerm</sc> Bridging Strategies With HighĀand <sc>LowĀDose</sc> Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A <sc>DoubleĀBlind</sc>, Randomized, <sc>PlaceboĀControlled</sc> Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1628-1637.	2.9	9
790	Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 269-278.	0.4	4
791	Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. <i>Rheumatology</i> , 2023, 62, 583-595.	0.9	3
792	Risk factors for adverse pregnancy outcomes in women with rheumatoid arthritis and follow-up of their offspring. <i>Clinical Rheumatology</i> , 2022, 41, 3135-3141.	1.0	3
793	Comparison between DAS28-ESR and DAS28- CRPus for patients with rheumatoid arthritis: application in a population of southern Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
794	Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. <i>Rheumatology International</i> , 0, , .	1.5	0
795	Implications of Persistent Pain in Patients With Rheumatoid Arthritis Despite Remission Status: Data From the KOBIO Registry. <i>Journal of Rheumatic Diseases</i> , 2022, , .	0.4	2
796	Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique. <i>RMD Open</i> , 2022, 8, e002458.	1.8	5
797	Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study. <i>PLoS ONE</i> , 2022, 17, e0271921.	1.1	1
798	Coping strategies, emotional distress and perceived disease severity in a cohort of patients with rheumatoid arthritis: a mediation analysis. <i>Rheumatology</i> , 2023, 62, 1078-1086.	0.9	4

#	ARTICLE	IF	CITATIONS
799	Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. <i>Modern Rheumatology</i> , 2023, 33, 647-656.	0.9	9
800	-Omic Approaches and Treatment Response in Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2022, 14, 1648.	2.0	5
801	Defining the targets in SLE management: insights and unmet gaps. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1483-1485.	0.5	5
802	Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2022, 184, 106405.	3.1	5
803	Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: <i>post hoc</i> analysis of SELECT-COMPARE. <i>Rheumatology</i> , 2023, 62, 1804-1813.	0.9	4
804	Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	8
805	Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	1
806	The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis â€” a pooled analysis of five randomised controlled trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211116.	1.2	6
807	Remission or Not Remission, Thatâ€™s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 1531-1547.	1.1	7
808	Need for a consensus definition of remission in paediatric asthma. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 755-756.	2.7	2
809	Overtreatment in rheumatoid arthritis: are there reasons for concern?. <i>RMD Open</i> , 2022, 8, e002212.	1.8	1
810	Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study. <i>PLoS ONE</i> , 2022, 17, e0273789.	1.1	1
811	Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
812	Favorable effect of a â€”second hitâ€™™ after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. <i>Rheumatology</i> , 0, , .	0.9	2
813	Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
814	American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 74-80.	0.5	23
816	American College of Rheumatology/<sc>EULAR</sc> Remission Criteria for Rheumatoid Arthritis: 2022 Revision. <i>Arthritis and Rheumatology</i> , 2023, 75, 15-22.	2.9	18
817	Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment. <i>Scientific Reports</i> , 2022, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
818	Prevalence of rheumatoid arthritis and diagnostic validity of a prediction score, in patients visiting orthopedic clinics in the Madinah region of Saudi Arabia: a retrospective cross-sectional study. <i>PeerJ</i> , 0, 10, e14362.	0.9	2
819	Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
820	Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
821	Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: Post-marketing surveillance study. <i>Modern Rheumatology</i> , 0, , .	0.9	0
822	A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002615.	1.8	3
823	The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	6
824	Rheumatoid Arthritis, A Laconic Review to understand their Basic Concept and Management Process. <i>Asian Journal of Pharmaceutical Research</i> , 2022, , 312-322.	0.2	3
825	Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2022, 18, 574-579.	0.2	0
826	Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 1851.	0.8	3
827	Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	10
828	Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate. <i>Rheumatology and Therapy</i> , 2023, 10, 375-386.	1.1	1
829	A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
830	Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. <i>RMD Open</i> , 2022, 8, e002658.	1.8	7
831	Greetings from the editor 2023. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 1-2.	0.5	4
832	Application of Laboratory Medicine in the Field of Oral Medicine. , 2022, 47, 167-173.		0
833	Synthesis, molecular modelling and docking studies of new thieno[2,3-b:4,5-b [€]] dipyridine compounds as antimicrobial agents. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104839.	2.3	1
836	MTHFR c.665C>T and c.1298A>C Polymorphisms in Tailoring Personalized Anti-TNF-Î± Therapy for Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4110.	1.8	2
837	Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1734.	1.0	5

#	ARTICLE	IF	CITATIONS
838	⁶⁸ Ga-FAPI PET/CT for Rheumatoid Arthritis: A Prospective Study. <i>Radiology</i> , 2023, 307, .	3.6	14
839	Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2023, 10, 707-727.	1.1	3
840	KW2449 ameliorates collagen-induced arthritis by inhibiting RIPK1-dependent necroptosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
841	14-3-3 ^γ Cytokine as a New Biomarker to Assess Rheumatoid Arthritis Disease Activity. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2023, 59, 141-153.	0.2	0
842	Feasibility of methotrexate discontinuation following tocilizumab and methotrexate combination therapy in patients with long-standing and advanced rheumatoid arthritis: a 3-year observational cohort study. <i>Fukushima Journal of Medical Sciences</i> , 2023, 69, 11-20.	0.1	0
844	Management of Rheumatoid Arthritis With a Digital Health Application. <i>JAMA Network Open</i> , 2023, 6, e238343.	2.8	8